Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy

By afschroeder • November 30, 2025

Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster JD, Rieder N, Dietmann G, Cannarile M, Cotter C, Hack SP, Cha E, Ishiguro T, Llovet JM, Zhu AX, Finn RS. Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy. Cell Rep Med. 2025 Nov 28:102473. doi: 10.1016/j.xcrm.2025.102473. Epub ahead of print. PMID: 41317730.

Tags: Atezolizumab, Bevacizumab, HCC, Hematology/Oncology, immunotherapy, liver cell lineages, mechanisms of response and resistance, molecular subtype, Publications

RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial

Chugh R, Singh A, Andelkovic V, Mallick AB, Brockstein B, Bui N, Chawla S, Choy E, Davis LE, Gounder M, Haddadin S, Kasper B, Kim[...]

Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis

Padula WV, Cohen BG, Steel P, Appukkuttan S, Kalayeh B, Rettig M. Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer:[...]

tRNA dosage regulates lineage dependency and resistance in prostate cancer

Kim YS, Arora S, Young D, Tsou A, Shiuan A, Wladyka CL, Rudoy D, Kim JY, Waters JA, Schuster SL, Coleman IM, Kapur M, Sobczyk[...]